- Home
- IMAB vs ADAG Comparison
IMAB vs ADAG Comparison
Compare IMAB & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ADAG
- Stock Information
- Founded
- IMAB 2014
- ADAG 2011
- Country
- IMAB United States
- ADAG China
- Employees
- IMAB N/A
- ADAG N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ADAG Health Care
- Exchange
- IMAB Nasdaq
- ADAG Nasdaq
- Market Cap
- IMAB 79.9M
- ADAG 81.9M
- IPO Year
- IMAB 2020
- ADAG 2021
- Fundamental
- Price
- IMAB $0.80
- ADAG $1.91
- Analyst Decision
- IMAB Strong Buy
- ADAG Strong Buy
- Analyst Count
- IMAB 3
- ADAG 1
- Target Price
- IMAB $8.00
- ADAG $8.00
- AVG Volume (30 Days)
- IMAB 234.1K
- ADAG 25.4K
- Earning Date
- IMAB 03-21-2025
- ADAG 03-17-2025
- Dividend Yield
- IMAB N/A
- ADAG N/A
- EPS Growth
- IMAB N/A
- ADAG N/A
- EPS
- IMAB N/A
- ADAG N/A
- Revenue
- IMAB $569,464.00
- ADAG $815,746.00
- Revenue This Year
- IMAB N/A
- ADAG N/A
- Revenue Next Year
- IMAB N/A
- ADAG $2.70
- P/E Ratio
- IMAB N/A
- ADAG N/A
- Revenue Growth
- IMAB N/A
- ADAG N/A
- 52 Week Low
- IMAB $0.76
- ADAG $1.64
- 52 Week High
- IMAB $2.00
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- IMAB 31.17
- ADAG 45.70
- Support Level
- IMAB $0.76
- ADAG $2.01
- Resistance Level
- IMAB $0.93
- ADAG $2.20
- Average True Range (ATR)
- IMAB 0.07
- ADAG 0.14
- MACD
- IMAB -0.01
- ADAG -0.00
- Stochastic Oscillator
- IMAB 18.03
- ADAG 14.29
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.